Novartis begins trial of new antimalarial drug
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
NOVARTIS is taking aim at drug-resistant malaria - a growing global problem - by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and Asia.
The Swiss drugmaker, which is working on the mid-stage Phase IIb trial programme with the group Medicines for Malaria Venture (MMV), said on Monday that it believed that its drug KAF156 could be a "game-changer".
Share with us your feedback on BT's products and services
TRENDING NOW
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
